Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression

Cancer Research

Volumn 60, Issue 7, 2000, Pages 2002-2006

  Wilentz, Robb E ^a   Iacobuzio Donahue, Christine A ^a   Argani, Pedram ^a   McCarthy, Denis M ^a   Parsons, Jennifer L ^a   Yeo, Charles J ^a   Kern, Scott E ^a   Hruban, Ralph H ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; TUMOR SUPPRESSOR PROTEIN DPC4; UNCLASSIFIED DRUG;

ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; GENE EXPRESSION; GENE INACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; DISEASE PROGRESSION; DNA-BINDING PROTEINS; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; PANCREATIC DUCTS; PANCREATIC NEOPLASMS; SMAD4 PROTEIN; TRANS-ACTIVATORS;

EID: 0034032009     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Vogelstein, B., and Kinzler, K. W. The multislep nature of cancer. Trends Genet., 9: 138-141, 1993.
2. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 61: 759-767, 1990.
3. Hruban, R. H., and Wilentz, R. E. Pancreas. In: N. Weidner, R. J. Cote, S. Suster, and L. M. Weiss (eds.), Modern Surgical Pathology. Philadelphia: W. B. Saunders Co., in press, 2000.
4. Brat, D. J., Lillemoe, K. D., Yeo, C. J., Warfield, P. B., and Hruban, R. H. Progression of pancreatic intraductal neoplasias (high-grade PanIN) to infiltrating adenocarcinoma of the pancreas. Am. J. Surg. Pathol., 22: 163-169, 1998.
5. Kozuka, S., Sassa, R., Taki, T., Masamoto, K., Nagasawa, S., Saga, S., Hasegawa, K., and Takeuchi, M. Relation of pancreatic duct hyperplasia to carcinoma. Cancer (Phila.), 43: 1418-1428, 1979.
6. Pour, P. M., Sayed, S., and Sayed, G. Hyperplastic, preneoplastic and neoplastic lesions found in 83 human pancreases. Am. J. Clin. Pathol., 77: 137-152, 1982.
7. Furukawa, T., Chiba, R., Kobari, M., Matsuno, S., Nagura, H., and Takahashi, T. Varying grades of epithelial atypia in the pancreatic ducts of humans. Classification based on morphometry and multivariate analysis and correlated with positive reactions of carcinoembryonic antigen. Arch. Pathol. Lab. Med., 118: 227-234, 1994.
8. Rozenblum, E., Schutte, M., Goggins, M., Hahn, S. A., Panzer, S., Zahurak, M., Goodman, S. N., Sohn, T. A., Hruban, R. H., Yeo, C. J., and Kern, S. E. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res., 57: 1731-1734, 1997.
9. Moskaluk, C. A., Hruban, R. H., and Kern, S. E. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res., 57: 2140-2143, 1997.
10. Wilentz, R. E., Geradts, J., Maynard, R., Offerhaus, G. J. A., Kang, M., Goggins, M., Yeo, C. J., Kern, S. E., and Hruban, R. H. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res., 58: 4740-4744, 1998.
11. DiGiuseppe, J. A., Hruban, R. H., Goodman, S. N., Polak, M., van den Berg, F. M., Allison, D. C., Cameron, J. L., and Offerhaus, G. J. A. Overexpression of p53 protein in adenocarcinoma of the pancreas. Am. J. Clin. Pathol., 101: 684-688, 1994.
12. Day, J. D., DiGiuseppe, J. A., Yeo, C. J., Loi-Goldman, M., Anderson, S., Kern, S. E., and Hruban, R. H. Immunohistochemical evaluation of HER-2/neu oncogene expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum. Pathol., 27: 119-124, 1996.
13. Yanagisawa, A., Ohtake, K., Ohashi, K., Hori, M., Kitagawa, T., Sugano, H., and Kato, Y. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res., 53: 953-956, 1993.
14. Tada, M., Ohashi, M., Shiratori, Y., Okudaira, T., Komatsu, Y., Kawabe, T., Yoshida, H., Machinami, R., Kishi, K., and Omata, M. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology, 110: 227-231, 1996.
15. Caldas, C., Hahn, S. A., Hruban, R. H., Redston, M. S., Yeo, C. J., and Kern, S. E. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res., 54: 3568-3573, 1994.
16. Hameed, M., Marrero, A. M., Conlon, K. C., Brennan, M. F., and Klimstra, D. S. Expression of p53 nucleophosphoprotein in in situ pancreatic ductal adenocarcinoma: an immunohistochemical analysis of 100 cases. Lab. Investig., 70: 132A, 1994.
17. Wilentz, R. E., Su, G. H., Dai, J. L., Sparks, A. B., Argani, P., Sohn, T. A., Yeo, C. J., Kern, S. E., and Hruban, R. H. Immunohistochemistry labeling for Dpc4 mirrors genetic status in pancreatic and peripancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am. J. Pathol., 156: 37-43, 2000.
18. Lüttges, J., Schlehe, B., Menke, M. A., Vogel, I., Henne-Bruns, D., and Klöppel, G. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. Cancer (Phila.). 85: 1703-1710, 1999.
19. Hahn, S. A., Schutte, M., Hoque, A. T. M. S., Moskaluk, C. A., daCosta, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., and Kern, S. E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (Washington DC), 271: 350-353, 1996.
20. Hahn, S. A., Hoque, A. T. M. S., Moskaluk, C. A., daCosta, L. T., Schutte, M., Rozenblum, E., Seymour, A., Weinstein, C. L., Yeo, C. J., Hruban, R. H., and Kern, S. E. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res., 56: 490-494, 1996.
21. Schutte, M., Hruban, R. H., Hedrick, L., Cho. K. R., Nadasdy, G. M., Weinstein, C. L., Bova, G. S., Isaacs, W. B., Cairns, P., Nawroz, H., Sidransky, D., Casero, R. A., Meltzer, P. S., Hahn, S. A., and Kern, S. E. DPC4 gene in various tumor types. Cancer Res., 56: 2527-2530, 1996.
22. Hoque, A. T., Hahn, S. A., Schutte, M., and Kern, S. E. DPC4 gene mutation in colitis associated neoplasia. Gut, 40: 120-122, 1997.
23. Hahn, S. A., Bartsch, D., Schroers, A., Galehdari, H., Becker, M., Ramaswamy, A., Schwarte-Waldhoff, I., Maschek, H., and Schmiegel, W. Mutations of the DPC4/ Smad4 gene in biliary tract carcinoma. Cancer Res., 58: 1124-1126, 1998.
24. Bartsch, D., Hahn, S. A., Danichevski, K. D., Ramaswamy, A., Bastian, D., Galehdari, H., Barth, P., Schmiegel, W., Simon, B., and Rothmund, M. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene, 18: 2367-2371, 1999.
25. Thiagalingam, S., Lengauer, C., Leach, F. S., Schutte, M., Hahn, S. A., Overhauser, J., Willson, J. K., Markowitz, S., Hamilton, S. R., Kern, S. E., Kinzler, K. W., and Vogelstein, B. Evaluation of candidate tumor suppressor genes on chromosome 18 in colorectal cancers. Nat. Genet., 13: 343-346, 1996.
26. Takagi, Y., Kohmura, H., Futamura, M., Kida, H., Tanemura, H., Shimokawa, K., and Saji, S. Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology. 111: 1369-1372, 1996.
27. DiGiuseppe, J. A., Yeo, C. J., and Hruban, R. H. Molecular biology and the diagnosis and treatment of adenocarcinoma of the pancreas. Adv. Anat. Pathol., 3: 139-155, 1996.
28. Hruban, R. H., and DiGiuseppe, J. A. K-ras mutations in pancreatic ductal proliferative lesions: author's reply. Am. J. Pathol., 145: 1548-1550, 1994.
29. Wilentz, R. E., and Hruban, R. H. Pathology of cancer of the pancreas. Surg. Oncol. Clin. N. Am., 7: 43-65, 1998.
30. Takaku, K., Oshima, M., Miyoshi, H., Matsui, M., Seldin, M. F., and Taketo, M. M. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell, 92: 645-656, 1998.
31. Goggins, M., Hruban, R. H., and Kern, S. E. Relationship of BRCA2 germline mutation and pancreatic cancer intra-ductal lesions. Am. J. Pathol., in press, 2000.
32. Terhune, P. G., Phifer, D. M., Tosteson, T. D., and Longnecker, D. S. K-ras mutation in focal proliferative lesions of human pancreas. Cancer Epidemiol. Biomark. Prev., 7: 515-521, 1998.
33. Hruban, R. H., van Mansfeld, A. D. M., Offerhaus, G. J. A., van Weering, D. H. J., Allison, D. C., Goodman, S. N., Kensler, T. W., Bose, K. K., Cameron, J. L., and Bos, J. L. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am. J. Pathol., 143: 545-554, 1993.
34. Maynard, R., Hruban, R. H., Schutte, M., Kern, S. E., and Geradts, J. Immunohistochemical reactivity of mutant p16 proteins in paraffin sections: a comparison of four antibodies. Mod. Pathol., 11: 187A, 1998.
35. Schutte, M., Hruban, R. H., Geradts, J., Maynard, R., Hilgers, W., Rabindran, S. K., Moskaluk, C. A., Hahn, S. A., Schwarte-Waldhoff, I., Schmiegel, W., Baylin, S. B., Kern, S. E., and Herman, J. G. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res., 57: 3126-3130, 1997.
36. Redston, M. S., Caldas, C., Seymour, A. B., Hruban, R. H., da Costa, L., Yeo, C. J., and Kern, S. E. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res., 54: 3025-3033, 1994.
37. Goggins, M., Schutte, M., Lu, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., Yeo, C. J., Jackson, C. E., Lynch, H. T., Hruban, R. H., and Kern, S. E. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res., 56: 5360-5364, 1996.